Criteria for NGS testing in MNs can reduce unnecessary tests, saving costs without affecting patient care quality. Six approval and six cancellation criteria guide appropriate NGS use, focusing on ...

A new editorial paper was published in Oncotarget's Volume 15 on July 2, 2024, entitled, "DDX41 and its unique contribution to myeloid leukemogenesis." In this new editorial, researcher Hirotaka ...

Patients with TP53/PPM1D mutations in their stem cell product had an increased risk of myeloid neoplasms in patients with Hodgkin lymphoma undergoing autologous stem cell transplant. While autologous ...

Phase Ib Study of Unesbulin (PTC596) Plus Dacarbazine for the Treatment of Locally Recurrent, Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma Therapy-related myeloid neoplasm (t-MN) ...

“[...] myeloid neoplasms associated with DDX41 variants likely exhibit a unique pathogenesis that diverges from the conventional understanding of myeloid neoplasms ...

Please provide your email address to receive an email when new articles are posted on . Older age, diminished platelet count could be factors associated with developing secondary leukemia after CAR-T.

Venetoclax (Venclexta) combined with a hypomethylating agent (HMA) -- the standard of care for older patients with acute myeloid leukemia (AML) -- appeared to be safe and effective in patients in ...

“Our findings demonstrate that the mutational landscape of BPDCN is similar to that observed in other myeloid neoplasms, and we identified CCDC50 as a potential biomarker for this disease.” “Our ...